MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:MYLGF
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Mirati Therapeutics (OTCMKTS:MYLGF)
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Banco Popolare (BPSAY), DAILY MAIL&GEN TST SPON (DMTGY), African Barrick Gold Ltd (ABGLY), Solvay S.A. (SVYZY), Tencent Holding (TCEHY), Nestle SA (NSRGY), Cable & Wireless Communications Plc (CWIXF), L'Oreal SA (LRLCY), Naspers (NPSNY), Softbank Corp. (SFTBY), Allianz SE (AZSEY), BASF SE (BASFY), Volkswagen AG (VLKAY), Reckitt Benckiser Group PLC (RBGLY), Australia & New Zealand Banking Group (ANZBY), National Australia Bank (NABZY), Heineken NV (HEINY) and Enel SpA (ENLAY).
How do I buy Mirati Therapeutics stock?
Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
MarketBeat Community Rating for Mirati Therapeutics (OTCMKTS MYLGF)MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mirati Therapeutics stock can currently be purchased for approximately $0.12.
Consensus Ratings for Mirati Therapeutics (OTCMKTS:MYLGF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Mirati Therapeutics (OTCMKTS:MYLGF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Mirati Therapeutics (OTCMKTS:MYLGF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Mirati Therapeutics (OTCMKTS:MYLGF)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS
Dividend History for Mirati Therapeutics (OTCMKTS:MYLGF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Mirati Therapeutics (OTCMKTS:MYLGF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Mirati Therapeutics (OTCMKTS:MYLGF)
Latest Headlines for Mirati Therapeutics (OTCMKTS:MYLGF)
No headlines for this company have been tracked by MarketBeat.com
Mirati Therapeutics (MYLGF) Chart for Sunday, June, 25, 2017